News | Heart Failure | February 22, 2017

New RightSTEPS Educational Initiative to Drive Change in Clinician Prescribing Behavior for Chronic Heart Failure

Blended-learning initiative provides comprehensive education to empower clinicians to take the RightSTEPS to treat the right patients with the right drugs at the right dose at the right time

ACC, Haymarket Medical Education, HME, myCME, RightSTEPS initiative, prescribing behavior, chronic heart failure

February 22, 2017 — The American College of Cardiology (ACC), Haymarket Medical Education (HME) and myCME have joined forces to develop RightSTEPS: Optimizing Medical Therapy for Chronic Heart Failure. This long-term education initiative aims to help clinicians follow prescribing guidelines to reduce hospitalizations and readmissions and to improve patient outcomes to address the 75 percent of chronic heart failure (HF) patients who do not receive optimal doses of guideline-recommended drugs.

Launching in 2017, with additional education to be added regularly throughout the year, the program is overseen by leading experts in HF treatment, including Akshay S. Desai, M.D., MPH, FACC, director, heart failure disease management, Cardiovascular Division, Brigham and Women’s Hospital and associate professor of ,edicine, Harvard Medical School. The curriculum includes American College of Cardiology/American Heart Association guideline-driven medical therapy, and it enables clinicians to:

  • Learn via a dedicated online Cardiology Learning Center on myCME offering self-paced, personalized educational activities that are eligible for up to 16 continuing medical education (CME)/continuing nursing education (CNE) complimentary credits, including individualized treatments for various gender and racial/ethnic populations;
  • Practice during face-to-face live meetings at regional healthcare systems, with parallel sessions for patients and caregivers at Veterans Affairs hospitals; and
  • Perform and receive customized online coaching that qualifies as a Centers for Medicare & Medicaid Services (CMS) Quality Payment Program Improvement Activity under the new Merit-based Incentive Payment System (MIPS).

“Improving heart health is at the core of the ACC’s mission,” said Desai, ACC RightSTEPS chair and course director. “With RightSTEPS, medical professionals treating heart failure patients have easier access to the tools they need to make informed, guideline-driven decisions and provide their patients with the highest quality care.”

“Successful treatment of chronic HF depends on both medical knowledge and ongoing dialogue,” said Priya Wanchoo, M.D., medical director of myCME. “We’re pleased the education we develop with the ACC for RightSTEPS will have a dedicated home on myCME. We believe it will provide clinicians a support center for their efforts in providing optimal patient care.”

Supported by an independent educational grant from Novartis Pharmaceuticals Corporation, the curriculum is designed for the range of clinicians who provide care for patients with chronic HF, including cardiologists, internists, primary care physicians, nurses, nurse practitioners and physician assistants. To further close the circle and improve performance, it includes education geared for patients with chronic HF and their caregivers.

For more information: www.mycme.com/rightsteps

Related Content

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement
News | Heart Failure | November 02, 2018
In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the...
Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

CHF Solutions' Aquadex FlexFlow System

News | Heart Failure | November 01, 2018
November 1, 2018 — Daxor Corp.
NHLBI Pauses CONCERT-HF Heart Failure Trial
News | Heart Failure | October 29, 2018
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is pausing the...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018
October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S
Ohio State First in U.S. to Test Shunt Device for Heart Failure
News | Heart Failure | October 04, 2018
The Ohio State University Wexner Medical Center is first in the country to test a new medical device designed to help...
Mitral Regurgitation Volume Reduced at One Year in REDUCE FMR Trial
News | Heart Failure | September 28, 2018
Heart failure patients who received the Carillon Mitral Contour System in the REDUCE FMR clinical trial showed a...
Cardiac Dimensions Randomizes First Patient in CARILLON Trial of Mitral Contour System
News | Heart Failure | September 20, 2018
Cardiac Dimensions announced the company has randomized its first patient in the CARILLON Pivotal Trial.
Overlay Init